Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced today that its Phase 3 KEYNOTE-689 trial met the primary endpoint of event-free survival (EFS) for KEYTRUDA® (pembrolizumab). This trial focused on using KEYTRUDA, Merck’s anti-PD-1 therapy,…
The AIDS Healthcare Foundation (AHF) has expressed support for Gilead’s recent decision to expand the availability of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic manufacturers. However, AHF emphasizes that key countries affected…
Marshall B. Ketchum University (MBKU) recently celebrated the outstanding achievements of its alumni at the 2024 Distinguished Alumni Awards Ceremony, held during its second annual homecoming event. This year, the university honored sixteen exceptional alumni for their significant contributions to…
GigaGen Inc., a biotechnology firm specializing in innovative antibody treatments for immunodeficiencies, infectious diseases, and cancers resistant to checkpoint inhibitors, has announced a new contract awarded by the Biomedical Advanced Research and Development Authority (BARDA). BARDA, part of the U.S.…
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and mAbxience, a majority-owned group by Fresenius Kabi with partial ownership from Insud Pharma, have announced a new global licensing agreement for the development of…
Allergan Aesthetics, a part of AbbVie, has announced its sixth consecutive year of partnering with Girls Inc. to encourage high school and college girls’ interest in STEM (science, technology, engineering, and mathematics) and provide valuable mentorship opportunities. “In 2023, women…
Amgen (NASDAQ: AMGN) has teamed up with actress, producer, and entrepreneur La La Anthony to highlight her personal experience with plaque psoriasis and inspire others to have open conversations with their doctors about how the condition impacts their daily lives.…
AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan). This review is for the treatment of adult patients…
AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). This designation is granted…
AIVITA Biomedical, Inc., a biotech firm focused on pioneering stem cell applications, has announced a licensing agreement with LevEllis, a global skincare retailer. This partnership grants LevEllis the exclusive worldwide marketing and distribution rights to AIVITA’s proprietary skincare formulations, previously…
ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics and technology company, and Biotheus Inc., a clinical-stage biotech specializing in biologics for oncology and inflammatory diseases, have announced the signing of a Material Transfer and Evaluation Agreement (MTEA). This agreement…
Arcus Biosciences, Inc. (NYSE: RCUS), a global biopharmaceutical company in the clinical stage, focused on developing innovative molecules and combination therapies for cancer patients, has announced a new collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership aims to evaluate the combination…